List of Tables
Table 1. Global Anti-Rheumatic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-Rheumatic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-Rheumatic Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-Rheumatic Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Anti-Rheumatic Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Anti-Rheumatic Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Anti-Rheumatic Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Rheumatic Drugs as of 2024)
Table 11. Global Anti-Rheumatic Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Anti-Rheumatic Drugs Companies Headquarters
Table 13. Global Anti-Rheumatic Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Anti-Rheumatic Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Anti-Rheumatic Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Anti-Rheumatic Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Anti-Rheumatic Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. Anti-Rheumatic Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 25. North America Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 27. Europe Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Anti-Rheumatic Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Anti-Rheumatic Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Novartis Corporation Information
Table 35. Novartis Description and Major Businesses
Table 36. Novartis Product Features and Attributes
Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Novartis Revenue Proportion by Product in 2024
Table 39. Novartis Revenue Proportion by Application in 2024
Table 40. Novartis Revenue Proportion by Geographic Area in 2024
Table 41. Novartis Anti-Rheumatic Drugs SWOT Analysis
Table 42. Novartis Recent Developments
Table 43. UCB Corporation Information
Table 44. UCB Description and Major Businesses
Table 45. UCB Product Features and Attributes
Table 46. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. UCB Revenue Proportion by Product in 2024
Table 48. UCB Revenue Proportion by Application in 2024
Table 49. UCB Revenue Proportion by Geographic Area in 2024
Table 50. UCB Anti-Rheumatic Drugs SWOT Analysis
Table 51. UCB Recent Developments
Table 52. AbbVie Corporation Information
Table 53. AbbVie Description and Major Businesses
Table 54. AbbVie Product Features and Attributes
Table 55. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. AbbVie Revenue Proportion by Product in 2024
Table 57. AbbVie Revenue Proportion by Application in 2024
Table 58. AbbVie Revenue Proportion by Geographic Area in 2024
Table 59. AbbVie Anti-Rheumatic Drugs SWOT Analysis
Table 60. AbbVie Recent Developments
Table 61. Bristol-Myers Squibb Corporation Information
Table 62. Bristol-Myers Squibb Description and Major Businesses
Table 63. Bristol-Myers Squibb Product Features and Attributes
Table 64. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bristol-Myers Squibb Revenue Proportion by Product in 2024
Table 66. Bristol-Myers Squibb Revenue Proportion by Application in 2024
Table 67. Bristol-Myers Squibb Revenue Proportion by Geographic Area in 2024
Table 68. Bristol-Myers Squibb Anti-Rheumatic Drugs SWOT Analysis
Table 69. Bristol-Myers Squibb Recent Developments
Table 70. Merck Corporation Information
Table 71. Merck Description and Major Businesses
Table 72. Merck Product Features and Attributes
Table 73. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Merck Revenue Proportion by Product in 2024
Table 75. Merck Revenue Proportion by Application in 2024
Table 76. Merck Revenue Proportion by Geographic Area in 2024
Table 77. Merck Anti-Rheumatic Drugs SWOT Analysis
Table 78. Merck Recent Developments
Table 79. HEYL Chemisch-pharmazeutische Fabrik Corporation Information
Table 80. HEYL Chemisch-pharmazeutische Fabrik Description and Major Businesses
Table 81. HEYL Chemisch-pharmazeutische Fabrik Product Features and Attributes
Table 82. HEYL Chemisch-pharmazeutische Fabrik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. HEYL Chemisch-pharmazeutische Fabrik Recent Developments
Table 84. Roche Corporation Information
Table 85. Roche Description and Major Businesses
Table 86. Roche Product Features and Attributes
Table 87. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Roche Recent Developments
Table 89. Johnson & Johnson Corporation Information
Table 90. Johnson & Johnson Description and Major Businesses
Table 91. Johnson & Johnson Product Features and Attributes
Table 92. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Johnson & Johnson Recent Developments
Table 94. Amgen Corporation Information
Table 95. Amgen Description and Major Businesses
Table 96. Amgen Product Features and Attributes
Table 97. Amgen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Amgen Recent Developments
Table 99. Pfizer Corporation Information
Table 100. Pfizer Description and Major Businesses
Table 101. Pfizer Product Features and Attributes
Table 102. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Pfizer Recent Developments
Table 104. GSK Corporation Information
Table 105. GSK Description and Major Businesses
Table 106. GSK Product Features and Attributes
Table 107. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. GSK Recent Developments
Table 109. Sanofi Corporation Information
Table 110. Sanofi Description and Major Businesses
Table 111. Sanofi Product Features and Attributes
Table 112. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Sanofi Recent Developments
Table 114. Abbott Laboratories Corporation Information
Table 115. Abbott Laboratories Description and Major Businesses
Table 116. Abbott Laboratories Product Features and Attributes
Table 117. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Abbott Laboratories Recent Developments
Table 119. Teva Pharmaceutical Corporation Information
Table 120. Teva Pharmaceutical Description and Major Businesses
Table 121. Teva Pharmaceutical Product Features and Attributes
Table 122. Teva Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Teva Pharmaceutical Recent Developments
Table 124. Eli Lilly and Company Corporation Information
Table 125. Eli Lilly and Company Description and Major Businesses
Table 126. Eli Lilly and Company Product Features and Attributes
Table 127. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Eli Lilly and Company Recent Developments
Table 129. Celltrion Corporation Information
Table 130. Celltrion Description and Major Businesses
Table 131. Celltrion Product Features and Attributes
Table 132. Celltrion Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Celltrion Recent Developments
Table 134. Astellas Pharma Corporation Information
Table 135. Astellas Pharma Description and Major Businesses
Table 136. Astellas Pharma Product Features and Attributes
Table 137. Astellas Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Astellas Pharma Recent Developments
Table 139. Simcere Corporation Information
Table 140. Simcere Description and Major Businesses
Table 141. Simcere Product Features and Attributes
Table 142. Simcere Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Simcere Recent Developments
Table 144. Daiichi Sankyo Corporation Information
Table 145. Daiichi Sankyo Description and Major Businesses
Table 146. Daiichi Sankyo Product Features and Attributes
Table 147. Daiichi Sankyo Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Daiichi Sankyo Recent Developments
Table 149. Asahi Kasei Corporation Information
Table 150. Asahi Kasei Description and Major Businesses
Table 151. Asahi Kasei Product Features and Attributes
Table 152. Asahi Kasei Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Asahi Kasei Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Rheumatic Drugs Product Picture
Figure 2. Global Anti-Rheumatic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Disease Modifying Anti-rheumatics Drugs (DMARD's) Product Picture
Figure 4. Nonsteroidal Anti-inflammatory Drugs (NSAID's) Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Uric Acid Drugs Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anti-Rheumatic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Anti-Rheumatic Drugs Report Years Considered
Figure 13. Global Anti-Rheumatic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 15. Global Anti-Rheumatic Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Anti-Rheumatic Drugs Revenue Market Share by Region (2020-2031)
Figure 17. Global Anti-Rheumatic Drugs Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Disease Modifying Anti-rheumatics Drugs (DMARD's) Revenue Market Share by Player in 2024
Figure 20. Nonsteroidal Anti-inflammatory Drugs (NSAID's) Revenue Market Share by Player in 2024
Figure 21. Corticosteroids Revenue Market Share by Player in 2024
Figure 22. Uric Acid Drugs Revenue Market Share by Player in 2024
Figure 23. Others Revenue Market Share by Player in 2024
Figure 24. Global Anti-Rheumatic Drugs Revenue Market Share by Type (2020-2031)
Figure 25. Global Anti-Rheumatic Drugs Revenue Market Share by Application (2020-2031)
Figure 26. North America Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 28. North America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 35. Europe Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. France Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. India Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 58. Central and South America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 64. South America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Anti-Rheumatic Drugs Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
